Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:7 Issue:8 Number:17 ISSN#:2563-5476
RCT
ACE Report #10576
Ace Report Cover Cannabis

Dronabinol effective in reducing neuropathic pain in multiple sclerosis after 48-week treatment


How to Cite

OrthoEvidence. Dronabinol effective in reducing neuropathic pain in multiple sclerosis after 48-week treatment. ACE Report. 2018;7(8):17. Available from: https://myorthoevidene.com/AceReport/Report/10576

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Dronabinol is a safe long-term treatment option for neuropathic pain patients

Eur Neurol. 2017;78(5-6):320-329.

Contributing Authors: S Schimrigk M Marziniak C Neubauer EM Kugler G Werner D Abramov-Sommariva

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

240 patients who had neuropathic pain that was associated with multiple sclerosis (MS) were randomly assigned to receive either dronabinol 7.5-15.0 mg daily for 16 weeks, or its respective placebo with the identical schedule. No significant differences in pain reduction and quality of life improvement were found in patients that received dronabinol compared to those that received placebo. In a fol...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE